A TREATMENT
TARGETED FOR ROS1
FACT
1%-2% of adults with non-small cell lung cancer (NSCLC) are diagnosed with an abnormal ROS1 gene. AUGTYRO is a treatment tailored to treat it, whether you are newly diagnosed or have been previously treated.
You’re not alone. Sign up for this complimentary program to learn about support and advocacy groups and get tools to help you during your journey.
KELLY’S STORY
Meet Kelly. When Kelly was diagnosed with stage 4 lung cancer, she tested positive for ROS1+ NSCLC. Then, her oncologist recommended treatment with AUGTYRO. Learn more about Kelly’s story.